Emirates, SA Tourism sign MoU

The world’s largest airline, Emirates, and South African Tourism have signed a Memorandum of Understanding (MoU) to jointly promote tourism and boost visitor arrivals and inbound traffic to South Africa from key markets across the airline’s network.

The MoU was signed on the side-lines of Arabian Travel Market by Badr Abbas, Emirates’ Senior Vice President Commercial Operations for Africa, and The South Africa Tourism’s Acting CEO, Themba Khumalo. Tourism Minister, Lindiwe Sisulu and Dubai Consul General, David Magabe, were also at the signing.

Adnan Kazim, Emirates’ Chief Commercial Officer, said the airline, which had more than 25 years invested in and grown operations to South Africa was working to restore its services to pre-pandemic levels.

This, he said, would “help generate more opportunities for travellers from around the world to experience South Africa’s unique natural experiences, world-renowned cuisine, and local culture”.

He said: “Emirates is well-placed to support the recovery of South Africa’s tourism sector and help raise the profile of the destination again, offering convenient connections from over 130 destinations, and providing even more links for travellers who want to explore beyond our three South African gateways through our four airline partners”.

Sisulu welcomed the signing of the MoU, citing the benefits it yielded for travel between South Africa and the Middle East.

She said: “We want to continue ensuring ease of access into South Africa for Middle Eastern travellers and this collaboration will assist us in elevating our trade efforts; in terms of packaging the destination.

“We look forward to welcoming more travellers from the Middle East, to experience the various quality assured products and experiences that cater for this market, including; family friendly accommodation establishments and activities, a diverse offering of cuisine as well as wildlife and safari”.

Khumalo said the Middle East was a critical market for South Africa, saying the partnership would be instrumental in ensuring ease of access to and from South Africa for travellers from the Middle East.

Aimed at supporting South Africa’s tourism recovery efforts, the partnership between Emirates and South African Tourism is part of the airline’s longstanding commitment to grow the tourism market in the country.

Under the MoU, Emirates will explore opportunities to promote South Africa and encourage travellers to experience the abundance of attractions that the country has to offer across its network of over 130 destinations.

He said South Africa Tourism will also work closely with the airline to support travel trade partners and tour operators across the Emirates’ network to develop and promote itineraries, introduce special packages and promotional giveaways, encourage incentives, among other marketing initiatives.

Both parties will also explore opportunities to collaborate on joint advertising and marketing campaigns, as well as familiarisation programmes to South Africa for travel trade and media representatives, among other initiatives. Emirates will also support the transport of South African Tourism’s marketing collaterals to select destinations in its network.

Emirates has been serving South Africa for 27 years, proudly connecting close to 20 million travellers to and from South Africa and Dubai and beyond to its global network, firmly establishing the airline as a long-term partner of South African aviation, tourism, and trade.

Today, the airline currently serves South Africa with 26 weekly flights, including double daily services to Johannesburg, daily services to Cape Town and five weekly flights to Durban.

Customers can also access popular regional destinations across South Africa via the airline’s codeshare agreements with South African Airways and Airlink, and interline agreements with FlySafair and Cemair.

 

 

Source: South African Government News Agency

Zenas BioPharma Submits Investigational New Drug Application in China for ZB001 for the Treatment of Thyroid Eye Disease

WALTHAM, Mass. and SHANGHAI, China, May 15, 2022 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients in need around the world, today announced the submission of an investigational new drug (IND) application to the China National Medical Products Administration (NMPA) for the initiation of a Phase 1/2 clinical study of ZB001 for the treatment of Thyroid Eye Disease (TED). This study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ZB001.

“The ZB001 IND submission to the NMPA marks a significant milestone for Zenas,” said Hua Mu, MD, PhD, Chief Executive Officer at Zenas. “There are currently no approved therapies for TED patients in China. Treatment options are limited and often involve high doses of steroids associated with serious side effects or surgical intervention. ZB001 has the potential to change the treatment paradigm for TED patients in China.”

ZB001 is a differentiated humanized monoclonal antibody targeting insulin-like growth factor 1 receptor (IGF-1R) for the treatment of TED. TED is a debilitating autoimmune disease that causes inflammation and fibrosis within the orbit of the eye, which can cause double vision, pain, and potential blindness. Patients with severe disease often require multiple remedial surgeries to the orbit, eye muscles and eyelids.

Zenas BioPharma licensed the exclusive rights to develop, manufacture and commercialize ZB001 (Viridian VRDN-001) and other compounds targeting IGF-1R in non-oncology indications in the greater area of China from Viridian Therapeutics, Inc. (Viridian) in October 2020. In October 2021, Viridian submitted an IND for VRDN-001 to the U.S. Food and Drug Administration and in December 2021 initiated a Phase 1/2 clinical trial to evaluate proof of concept in TED patients in North America.

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company based in the USA and China committed to becoming a leader in the development and commercialization of immune-based therapies for patients in the US, China and around the world. Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.

Investor and Media Contact:
Joe Farmer
Zenas BioPharma
IR@zenasbio.com

Zenas BioPharma soumet une demande en Chine pour un nouveau médicament expérimental pour ZB001 portant sur le traitement de l’ophtalmopathie thyroïdienne

WALTHAM, Massachusetts et SHANGHAI, Chine, 16 mai 2022 (GLOBE NEWSWIRE) — Zenas BioPharma, une société biopharmaceutique mondiale déterminée à devenir un leader dans le développement et la commercialisation de traitements immunitaires pour les patients dans le besoin dans le monde entier, a annoncé aujourd’hui la soumission d’une demande pour un nouveau médicament expérimental (IND) à la China National Medical Products Administration (NMPA ou Administration nationale des produits médicaux de la Chine) pour le lancement d’une étude clinique de phase 1/2 sur ZB001 portant sur le traitement de l’ophtalmopathie thyroïdienne (TED). Cette étude vise à évaluer l’innocuité, la tolérance, la pharmacocinétique et l’efficacité préliminaire de ZB001.

« La soumission de l’IND auprès de la NMPA pour pour ZB001 marque une étape importante pour Zenas », a déclaré Hua Mu, MD, PhD, président-directeur général de Zenas. « Il n’existe actuellement aucun traitement approuvé pour les patients atteints de TED en Chine. Les options de traitement sont limitées et impliquent souvent des doses élevées de stéroïdes associées à des effets secondaires graves ou à une intervention chirurgicale. ZB001 a le potentiel de changer le paradigme de traitement pour les patients atteints de TED en Chine. »

ZB001 est un anticorps monoclonal humanisé différencié ciblant le récepteur du facteur de croissance analogue à l’insuline 1 (IGF-1R) pour le traitement de la TED. La TED est une maladie auto-immune invalidante qui provoque une inflammation et une fibrose dans l’orbite de l’œil, ce qui peut causer une vision double, des douleurs et une cécité potentielle. Les patients gravement atteints ont souvent besoin de plusieurs interventions chirurgicales correctives sur l’orbite, les muscles oculaires et les sourcils.

En octobre 2020, Zenas BioPharma a acquis auprès de Viridian Therapeutics, Inc. (Viridian) les droits exclusifs de développement, de fabrication et de commercialisation de ZB001 et d’autres composés ciblant l’IGF-1R dans les indications non oncologiques dans la Grande Chine. En novembre 2021, Viridian a déposé une demande d’IND pour ZB001 (appelé VRDN-001 par Viridian) auprès de la Food and Drug Administration des États-Unis et a lancé en décembre 2021 un essai clinique de phase 1/2 visant à évaluer la preuve de concept chez les patients atteints de TED aux États-Unis.

À propos de Zenas BioPharma

Zenas BioPharma est une société biopharmaceutique mondiale basée en Chine et aux États-Unis déterminée à devenir un leader dans le développement et la commercialisation de traitements immunitaires pour les patients aux États-Unis, en Chine et dans le monde entier. Zenas fait rapidement progresser un vaste pipeline de traitements innovants qui continue de s’accroître grâce à notre stratégie de développement commercial fructueuse. Notre équipe de direction expérimentée et notre réseau de partenaires commerciaux stimulent l’excellence opérationnelle pour apporter des thérapies potentiellement transformatrices afin d’améliorer la vie des personnes confrontées à des maladies rares et auto-immunes. Pour tout complément d’information sur Zenas BioPharma, veuillez consulter le site www.zenasbio.com et nous suivre sur Twitter à l’adresse @ZenasBioPharma et LinkedIn.

Contact auprès des investisseurs et des médias :
Joe Farmer
Zenas BioPharma
IR@zenasbio.com

Zenas BioPharma solicita aprovação do medicamento investigacional ZB001 na China para o tratamento de Doença Ocular da Tireoide

WALTHAM, Mass. e XANGAI, China, May 15, 2022 (GLOBE NEWSWIRE) — A Zenas BioPharma, uma empresa biofarmacêutica global comprometida em se tornar líder no desenvolvimento e comercialização de terapias imunológicas para pacientes necessitados em todo o mundo, anunciou hoje que solicitou a aprovação de um novo investigacional (IND) à Administração Nacional de Produtos Médicos da China (NMPA) para o início de um estudo clínico de Fase 1/2 do ZB001 para o tratamento da Doença Ocular da Tireoide (TED). Este estudo foi projetado para avaliar a segurança, tolerabilidade, farmacocinética e eficácia preliminar do ZB001.

“A solicitação de aprovação do ZB001 IND ao NMPA é um marco significativo para a Zenas”, disse Hua Mu, MD, PhD, Diretor Executivo da Zenas. “No momento não existe nenhuma terapia aprovada para pacientes com TED na China. As opções de tratamento são limitadas e muitas vezes envolvem altas doses de esteroides que resultam em efeitos colaterais graves ou intervenção cirúrgica. O ZB001 tem o potencial de mudar o paradigma do tratamento para pacientes com TED na China.”

O ZB001 é um anticorpo monoclonal humanizado diferenciado que direciona o receptor de fator de crescimento semelhante à insulina 1 (IGF-1R) para o tratamento de TED. TED é uma doença autoimune debilitante que causa inflamação e fibrose dentro da órbita do olho, podendo causar visão dupla, dor e cegueira em potencial. Pacientes com doença grave muitas vezes requerem múltiplas cirurgias corretivas da órbita, músculos dos olhos e pálpebras.

A Zenas BioPharma licenciou os direitos exclusivos para desenvolver, fabricar e comercializar o ZB001 e outros compostos direcionados ao IGF-1R em indicações não oncológicas na Grande China da Viridian Therapeutics, Inc. (Viridian) em outubro de 2020. Em novembro de 2021, a Viridian solicitou um IND para o ZB001 (VRDN-001 na Viridian) à Food and Drug Administration dos EUA e, em dezembro de 2021, deu início a um ensaio clínico de Fase 1/2 para avaliar a prova de conceito em pacientes com TED nos EUA.

Sobre a Zenas BioPharma

A Zenas BioPharma é uma empresa biofarmacêutica mundial com sedes nos EUA e na China, comprometida em se tornar líder global no desenvolvimento e comercialização de terapias imunológicas para pacientes nos EUA, China e em todo o mundo. A Zenas está avançando rapidamente um vasto pipeline de terapêuticas inovadoras que continua a crescer por meio da nossa estratégia de desenvolvimento de negócios de sucesso. Nossa experiente equipe de liderança e rede de parceiros de negócios impulsionam a excelência operacional para oferecer terapias potencialmente transformadoras para melhorar a vida das pessoas que enfrentam doenças autoimunes e raras. Para mais informação sobre a Zenas BioPharma, visite www.zenasbio.com siga-nos no Twitter em @ZenasBioPharma e LinkedIn.

Contato com Investidores e com a Mídia:
Joe Farmer
Zenas BioPharma
IR@zenasbio.com